Earnings Call · Q1 FY2024·2024-05-14

Q1 24EPS +3.70%·Rev n/aQ4 23EPS +86.11%·Rev n/aQ3 23EPS +6.98%·Rev n/aQ2 23EPS +21.82%·Rev n/a⚠ consensus missing

ENDRA Life Sciences Inc. NDRA

Yvonne Briggs — Investor Relations

Francois Michelon — Chief Executive Officer

Unknown

Michael Thornton — Vice President of Regulatory Affairs

Irina Pestrikova — Chief Financial Officer

In summary, we remain committed to driving innovation and our market presence through the following 4 levers

−2.6%1d on move date−2.7% vs SPY3d−2.8%5d+2.7%

Research tier

Behavioral profile computed for 6 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more NDRA calls or request research access.

More NDRA calls Browse calls Request research access